Hepatitis G virus (HGV) is a newly described RNA virus that is parenterally transmitted and has been found frequently in patients with chronic hepatitis C infection. To determine the impact of hepatitis G virus co-infection on morbidity and mortality following liver transplantation, we measured HGV
Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside
β Scribed by George H. Scullard; Ljudevit L. Andres; Harry B. Greenberg; Joseph L. Smith; Vinod K. Sawhney; E. Andrew Neal; Anmol S. Mahal; Hans Popper; Thomas C. Merigan; William S. Robinson; Dr. Peter B. Gregory
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 398 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Twelve of 32 patients lost HBeAg and DNA polymerase from their serum after completing antiviral therapy with interferon and/or adenine arabinoside. Three lost serum HBsAg as well. Loss of corresponding viral markers from hepatic tissue was also seen. There was improvement in symptoms, hepatic tests, and histologic findings in the 12 patients whose viral markers disappeared when compared to the 20 whose viral markers persisted despite treatment. These findings provide support for the use of antiviral agents in hepatitis B positive chronic liver disease.
π SIMILAR VOLUMES
## Abstract Although occult hepatitis B virus (HBV) infection (HBVβDNA in serum in the absence of hepatitis B surface antigen [HBsAg]) is common in chronic hepatitis C, its characteristics are not well known. In this work, the presence of HBVβDNA (by polymerase chain reaction; PCR) and its distribu
Virus variants escaping from host immunity may be implicated in the pathogenesis of hepatitis B virus (HBV) infection. In this cross-sectional study, the association was evaluated of the frequency of amino acid variation within the immunogenic epitopes of surface gene with different disease stages o
To examine the long-term effect of interferon (IFN) therapy in patients with chronic hepatitis B virus (HBV) infection, particularly on survival and hepatocellular carcinoma (HCC) prevention, 101 male patients with chronic hepatitis B in a randomized controlled trial were followed up for 1.1 to 11.5